<DOC>
	<DOCNO>NCT01383499</DOCNO>
	<brief_summary>The aim trial select optimum dose may select base bronchodilator efficacy , safety evaluation pharmacokinetics tiotropium bromide .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Tiotropium Children 6 11 Years Old With Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Patients must meet follow inclusion criterion eligible enrollment study : 1 . All patient ' parent ( legally accept caregiver ) must sign date inform consent prior study procedure include medication washout restriction . In addition , inform assent suitable age group obtain patient . 2 . Male female patient 6 11 year age ( 1 day prior 12th birthday Visit 1 ) . 3 . All patient must least 6month history asthma time enrolment trial . 4 . All patient must maintenance treatment inhaled corticosteroid stable medium dose patient eligible =200 µg =400 µg Budesonide DPI equivalent . 5 . All patient must symptomatic ( partly control ) Visit 1 ( screen ) prior randomisation Visit 2 define ACQ mean score =1.5 . 6 . All patient must prebronchodilator FEV1 =60 % =90 % predict normal Visit 1 . Variation absolute FEV1 value Visit 2 ( predose ) compare value Visit 2 ( prebronchodilator ) must within ± 30 % . 7 . All patient must demonstrate increase FEV1 =12 % 15 30 min . 200 µg salbutamol ( albuterol ) Visit 1 . 8 . Patients must able inhale Respimat® inhaler correctly . 9 . Patients must able perform trial related procedure include technically acceptable spirometric manoeuvre accord current ATS/ERS standard use electronic diary/peak flow meter . Exclusion criterion : Patients follow characteristic eligible entry study : 1 . Patients significant disease asthma . 2 . Patients clinically relevant abnormal screen haematology blood chemistry exclude abnormality defines significant disease define exclusion criterion 1 . For participation PK sampling , haemoglobin le 11.3 g/dL regard exclusion criterion . 3 . Patients history congenital acquire heart disease , patient hospitalise cardiac syncope failure past year . 4 . Patients unstable lifethreatening cardiac arrhythmia , include cardiac arrhythmia require intervention ( e.g . pacemaker implantation , catheter ablation etc . ) change drug therapy within past year . 5 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . 6 . Patients clinically significant lung disease asthma , CF , bronchopulmonary dysplasia . 7 . Patients know active tuberculosis . 8 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 . 9 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program 6 week prior screen visit ( Visit 1 ) . 10 . Patients know hypersensitivity anticholinergic drug , BAC , EDTA components tiotropium inhalation solution . 11 . Patients know narrowangle glaucoma , disease anticholinergic treatment contraindicate . 12 . Patients moderate severe renal impairment , define creatinine clearance &lt; 50 mL/min./1.73 m2 BSA , tiotropium predominantly renally excrete drug .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>